Memphasys Stock

Equities

MEM

AU000000MEM5

Biotechnology & Medical Research

Market Closed - Australian S.E. 08:04:25 2024-04-21 pm EDT 5-day change 1st Jan Change
0.008 AUD -11.11% Intraday chart for Memphasys -11.11% -33.33%
Dynamic Chart
1 week-11.11%
Current month-20.00%
1 month-20.00%
3 months-38.46%
6 months-16.50%
Current year-33.33%
More quotes
1 week
0.01
Extreme 0.008
0.01
1 month
0.01
Extreme 0.007
0.01
3 years
0.01
Extreme 0.007
0.11
5 years
0.01
Extreme 0.007
0.15
10 years
0.01
Extreme 0.007
0.70
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-03-26
Director of Finance/CFO - -
Chief Operating Officer - 23-04-23
Members of the board TitleAgeSince
Chairman - 22-04-25
Director/Board Member 59 20-03-11
Chief Executive Officer - 23-03-26
More insiders
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing novel medical devices, diagnostics, and media with applications to assisted reproduction technology (ART) in humans and animals. Its reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company's product pipeline includes Felix, ROSA, and AI-Port. The Felix is a patented, automated device for quickly separating high quality sperm from semen for use in human in vitro fertilization (IVF) procedures without causing damage to DNA. Felix has a sizable target market worldwide. The Company’s ROSA is an in vitro diagnostic that assesses semen and blood samples for the presence of oxidative stress. The AI-Port stores and transports animal semen for artificial insemination (AI) for up to four days without the harmful effects of freezing sperm used in standard AI procedures in livestock.
More about the company